Q3 2023 Results

Company overview Financial review Conclusions Appendix References 2023 performance continues our track record of consistent top-line growth and core margin expansion Continuing operations¹ performance, numbers restated post-Sandoz spin-off Net sales % growth % cc, USD bn Core Oplnc² % growth % cc, USD bn 5% 7% 9% 12% 10% 10% 16% 21% 19% 19% Core margin² (%), growth bps cc vs. PY 35.1 36.2 FINANCIAL PROFILE +290bps 37.4 37.1 36.9 FY 22 42.2 Q1 23 Q2 23 Q3 23 10.8 11.4 11.8 9M 23 34.0 FY 22 14.8 Q1 23 3.9 Q2 23 4.2 Q3 23 4.4 9M 23 12.6 FY 22 Q1 23 Q2 23 Q3 23 9M 23 In USD bn 1. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities results and constant currencies are non-IFRS measures. Details regarding non-IFRS measures can be found starting on page 48 of the Condensed Interim Financial Report. 2. Core Unless otherwise noted, all growth rates refer to same period in PY. 23 Investor Relations | Q3 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation